ANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full-year 2016 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Guggenheim Raises Price Target on ANI Pharma (ANIP) Following 2Q Earnings Report
August 4, 2016 3:49 PM EDTGuggenheim reiterated a Buy rating on ANI Pharmaceuticals (NASDAQ: ANIP), and raised the price target to $80.00 (from $65.00), following the company's 2Q earnings report. ANIP reported adjusted diluted EPS of $1.11, $0.31 higher than consensus estimates. ANIP raised its '16 EPS guidance range from $3.54-$3.91 to... More
ANI Pharma (ANIP) Tops Q2 EPS by 34c; Boosts FY16 Outlook
August 4, 2016 8:43 AM EDTANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $1.11, $0.34 better than the analyst estimate of $0.77. Revenue for the quarter came in at $31.34 million versus the consensus estimate of $27.63 million.
GUIDANCE:
ANI Pharma sees FY2016 EPS of $4.00-$4.25, versus the consensus... More
